View Cart
My AccountInfectious Disease Diagnostic Solutions
Microbix Phone+1803294983432Microbix Emailcustomer.service@microbix.com
Microbix Logo
Request Catalogue Contact Us
  • Services
    • Assay Development Solutions
    • Custom Vial Filling Services
  • Products
    • Reference Materials (QUANTDx™)
    • Antigens
      • All Antigens
      • Childhood Disease Antigens
      • Dengue Antigens
      • STI Antigens
      • ToRCH Antigens
      • Respiratory Antigens
      • Other Antigens
    • External Quality Controls (QAPs™)
      • All External QC Products
      • Respiratory Viral Panel
      • STI Panel
      • HPV Panel
      • Gastrointestinal Panel
      • Genital Ulcer Panel
      • Vaginal Infections Panel
      • ONBOARDx Kits
      • Proficiency Testing Panel
      • Technical Resources
    • DxTM™ Viral Transport Medium
    • Control Elution Buffer
    • Kinlytic (Urokinase)
  • About
    • Who We Are
    • Who We Work With
    • Quality
    • Board of Directors
    • Our Senior Team
    • Careers
  • Resources
    • Catalogues & Brochures
    • White Papers
    • Poster Publication
    • Podcasts
  • Investors
    • News Releases
    • Financial Reports
    • Corporate Presentations
    • Analyst Coverage
    • Corporate Governance
    • Stock Information
Contact Us

Microbix Supporting Australian Point-of-Care Testing Program

by Pavel Zhelev | Mar 1, 2023 | News Releases

QAPs used in Diagnostic Testing for STIs in Remote Communities MISSISSAUGA, CANADA, March 1, 2023 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that its Quality Assessment Products...
Microbix Reports Results for Q1 Fiscal 2023 – Sales of $2.5 million, Net Loss of $1.3 million

Microbix Reports Results for Q1 Fiscal 2023 – Sales of $2.5 million, Net Loss of $1.3 million

by Pavel Zhelev | Feb 9, 2023 | News Releases

Sales of $2.5 million, Net Loss of $1.3 million MISSISSAUGA, February 9, 2023 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, reports results for its first quarter ended December 31, 2022...

Microbix Presenting Results of Collaboration with Health PEI

by Pavel Zhelev | Feb 6, 2023 | News Releases

QAPs for HPV Test Verification within Cervical Cancer Screening Program MISSISSAUGA, CANADA, February 6, 2023 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it will be presenting...

Microbix Launches QAP to Support “Monkeypox” Testing

by Pavel Zhelev | Jan 30, 2023 | News Releases

Driven by Customer Requests, Mpox Test Control Now Available MISSISSAUGA, CANADA, January 30, 2023 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it is launching a new quality...
Microbix Reports Results for Q1 Fiscal 2023 – Sales of $2.5 million, Net Loss of $1.3 million

Microbix Reports Record Sales for Fiscal 2022

by Pavel Zhelev | Dec 22, 2022 | Blog, News Releases

Record Sales of $19.1 million, Net Earnings of $1.8 million MISSISSAUGA, December 22, 2022 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, reports results for its year and fourth quarter...
« Older Entries
Next Entries »
  • Investors
  • Legal
  • Contact
  • News Releases
  • Accessibility
  • Careers
Microbix Funded By
Lab Image Lab Image

Get the Latest from Microbix—Straight to Your Inbox!

Stay up to date with news releases, product updates, tradeshows and conference information, and newsletters.


    Maybe later, science waits for no one